'Health Economics' and the evolution of economic evaluation of health technologies

Health Economics

Volumn 21, Issue 1, 2012, Pages 13-18

  Hutton, John ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; CONCEPTUAL FRAMEWORK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; ECONOMIC ASPECT; ECONOMIC EVALUATION; FEASIBILITY STUDY; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; WILLINGNESS TO PAY;

COMPARATIVE EFFECTIVENESS RESEARCH; COSTS AND COST ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; DELIVERY OF HEALTH CARE; ECONOMICS, MEDICAL; HUMANS; MODELS, ECONOMIC; PATIENT ACCEPTANCE OF HEALTH CARE; POLICY MAKING; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 82955176928     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1818     Document Type: Article

References (35)

1. de Bekker-Grob EW, Ryan M, Gerard K,. 2010. Discrete choice experiments in health economics: a review of the literature. Health Economics. DOI: 10.1002/hec.1697
2. Birch S, Gafni A,. 2002. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Economics 11 (3): 185-191.
3. Brazier J, Roberts J, Tsuchiya A, Busschbach J,. 2004. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics 13 (9): 873-884.
4. Briggs A, Clark T, Wolstenholme J, Clarke P,. 2003. Missingâ∥. presumed at random: cost-analysis of incomplete data. Health Economics 12 (5): 377-392.
5. Briggs A, Sculpher M,. 1995. Sensitivity analysis in economic evaluation: a review of published studies. Health Economics 4 (5): 355-371.
6. Briggs A, Sculpher M, Buxton M,. 1994. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Economics 3 (2): 95-104
7. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al,. 1997. Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life. Health Economics 6 (3): 217-227.
8. Cairns J,. 1992 Discounting and health benefits: Another Perspective. Health Economics 1 (1): 76-79.
9. Chalkidou K, Culyer A, Naidoo B, Littlejohns P,. 2008. Cost-effective public health guidance: asking questions from the decision-maker's viewpoint. Health Economics 17 (3): 441-448.
10. Claxton K, Posnett J,. 1996 An economic approach to clinical trial design and research priority-setting. Health Economics 5 (6): 513-524.
11. Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, et al,. 2006. Discounting and cost-effectiveness in NICE-stepping back to sort out a confusion. Health Economics 15 (1): 1-4.
12. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al,. 2005. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 14 (4): 339-347.
13. Department of Health: Medicines, Pharmacy and Industry Group. 2010. A new value-based approach to the pricing of branded medicines: a consultation. Department of Health: London.
14. Dolan P, Gudex C, Kind P, Williams A,. 1996. The time trade-off method: Results from a general population study. Health Economics 5 (2): 141-154.
15. Donaldson C, Hundley V, McIntosh E,. 1996. Using economics alongside clinical trials: Why we cannot choose the evaluation technique in advance. Health Economics 5 (3): 267-269.
16. Dowie J., 1997. Clinical Trials and Economic Evaluations? No, There are Only Evaluations. Health Economics 6 (1): 87-89.
17. Fenwick E, Claxton K, Sculpher M,. 2001. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 10 (8): 779-787.
18. Gerard K, Mooney G,. 1993. Qaly league tables: Handle with care. Health Economics 2 (1): 59-64.
19. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F,. 2007. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Economics 16 (3): 307-317.
20. Gravelle H, Smith D,. 2001. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Economics 10 (7): 587-599.
21. Hoch JS, Briggs AH, Willan AR,. 2002. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics 11 (5): 415-430.
22. Hutton J, Maynard A,. 2000. A Nice Challenge for Health Economics. Health Economics 9 (2): 89-93.
23. Lancsar E, Savage E,. 2004. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory. Health Economics 13 (9): 901-907.
24. Mishan EJ,. 1971. Cost benefit analysis. George Allen & Unwin: London.
25. National Institute for Clinical Excellence. 2001. Guidance for Manufacturers and Sponsors. Technology Appraisals Process Series 5. NICE: London.
26. National Institute for Clinical Excellence. 2004. Guide to the Methods of Technology Appraisal. NICE: London.
27. Nord E., 1994. The qaly-a measure of social value rather than individual utility? Health Economics 3 (2): 89-93.
28. Parsonage M, Neuburger H,. 1992. Discounting and health benefits. Health Economics 1 (1): 71-76.
29. Sculpher MJ, Claxton K, Drummond MJ, McCabe C,. 2006. Whither trial-based economic evaluation for health care decision making? Health Economics 15 (7): 677-687.
30. Sheldon TA,. 1996. Problems of using modelling in the economic evaluation of health care. Health Economics 5 (1): 1-11.
31. Sugden R, Williams A,. 1978. The principles of practical cost-benefit analysis. Oxford University Press: Oxford.
32. Van Hout BA,. 1998. Discounting costs and effects: a reconsideration. Health Economics 7 (7): 581-594.
33. Van Hout BA, Al MJ, Gordon GS, Rutten FFH,. 1994. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 3 (5): 309-319.
34. Willan AR, Briggs AH, Hoch JS,. 2004. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics 13 (5): 461-475.
35. Willke RJ, Glick HA, Polsky D, Schulman K,. 1998. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Economics 7 (6): 481-493.